bladder cancer

Test could help detect bladder cancer recurrenceAn easy-to-administer urine test looking for telomerase reverse transcriptase mutations helps detect recurring urothelial bladder cancer, especially non-muscle-invasive bladder cancer, early on, according to a new study.
How will immunotherapy change the future of bladder Ca care?Urology Times reached out to three urologists (selected randomly and asked them each the following question: How will immunotherapy change the future of bladder Ca care?
New products: Holmium laser increases stone ablation volumeOther products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Immuno-oncology bladder drug wins approvalSoon after approving the same drug for metastatic Merkel cell carcinoma, FDA approved immuno-oncology avelumab (Bavencio) for locally advanced or metastatic urothelial carcinoma.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Bladder cancer test shows high sensitivityThe noninvasive molecular test for detecting recurrent urothelial carcinoma also demonstrates high negative predictive value in a prospective study.
Some post-cystectomy symptoms persist for 3 monthsNew research suggests that post-surgery symptoms may last for at least 3 months in cystectomy patients and worsen over time in some cases, posing unique management challenges for urologists.
Radical cystectomy for bladder cancer: Tools vs. techniqueThe purpose of this article is to discuss important principles of radical cystectomy, whether performed using the open, laparoscopic, or robotic approach.
New bladder cancer, kidney disease therapies availableFDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.